Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirabegron for prevention of heart failure in structural heart disease
ISRCTN65055502Phase 2Completed
- Sponsor
- UCLouvain
- Start
- Mar 2016
- Modality
- Small Molecules
01
Overview
Phase 2, randomised trial in heart failure with preserved ejection fraction (HFpEF) and Structural Cardiac Abnormality comparing Mirabegron with Placebo (2 arms). Primary endpoints: Change in left ventricular mass index and Change in diastolic function (E/e'). Started Mar 2016; status: completed.
02
Drugs
mirabegron
03
Conditions
heart failure with preserved ejection fraction (HFpEF)Structural Cardiac Abnormality
Beyond the preview
Go deeper on ISRCTN65055502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN65055502.